NVCR vs. SOLV, SNN, PEN, GKOS, STVN, BLCO, INSP, NARI, PRCT, and NVST
Should you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry.
NovoCure vs.
NovoCure (NASDAQ:NVCR) and Solventum (NYSE:SOLV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
84.6% of NovoCure shares are owned by institutional investors. 6.3% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
NovoCure received 476 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 63.68% of users gave NovoCure an outperform vote while only 5.56% of users gave Solventum an outperform vote.
Solventum has lower revenue, but higher earnings than NovoCure.
In the previous week, NovoCure had 16 more articles in the media than Solventum. MarketBeat recorded 21 mentions for NovoCure and 5 mentions for Solventum. Solventum's average media sentiment score of 0.87 beat NovoCure's score of 0.67 indicating that Solventum is being referred to more favorably in the news media.
Solventum has a net margin of 0.00% compared to NovoCure's net margin of -25.93%. Solventum's return on equity of 0.00% beat NovoCure's return on equity.
NovoCure currently has a consensus target price of $32.67, suggesting a potential upside of 24.82%. Solventum has a consensus target price of $68.29, suggesting a potential downside of 7.21%. Given NovoCure's stronger consensus rating and higher possible upside, analysts plainly believe NovoCure is more favorable than Solventum.
Summary
NovoCure beats Solventum on 9 of the 13 factors compared between the two stocks.
Get NovoCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovoCure Competitors List
Related Companies and Tools
This page (NASDAQ:NVCR) was last updated on 1/20/2025 by MarketBeat.com Staff
Free NVCR Stock Alerts